Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 213 entries
Sorted by: Best Match Show Resources per page
Incidence of diabetes following ramipril or rosiglitazone withdrawal

program design

[No authors listed]
GSID: X-jlTL2_JlEJ
DREAM Trial Investigators - Diabetes Care, 2011 - Am Diabetes Assoc

OBJECTIVE To examine the impact of withdrawing rosiglitazone and ramipril medication on diabetes incidence after closeout of the Diabetes REduction Assessment with ramipril and …

Cite
DREAM Trial Investigators. (2011). Incidence of diabetes following ramipril or rosiglitazone withdrawal. Diabetes Care, 34(6), 1265-1269.
DREAM Trial Investigators. "Incidence of diabetes following ramipril or rosiglitazone withdrawal." Diabetes Care 34.6 (2011): 1265-1269.
Copy Download .nbib Format: MLA
Severe hyponatraemia during therapy with ramipril.

BMJ case reports

Ramasamy I.
PMID: 21918655
BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.06.2009.1932. Epub 2009 Sep 15.

An older patient who was being treated with ramipril, chlorpromazine and aspirin presented with hypotension and serum sodium of 119 mmol/litre. The patient was treated with intravenous saline and all drug therapy was stopped. Serum sodium rose following fluid...

Cite
Ramasamy I. Severe hyponatraemia during therapy with ramipril. BMJ Case Rep. 2009;2009doi: 10.1136/bcr.06.2009.1932.
Ramasamy, I. (2009). Severe hyponatraemia during therapy with ramipril. BMJ case reports, 2009. https://doi.org/10.1136/bcr.06.2009.1932
Ramasamy, I. "Severe hyponatraemia during therapy with ramipril." BMJ case reports vol. 2009 (2009). doi: https://doi.org/10.1136/bcr.06.2009.1932
Ramasamy I. Severe hyponatraemia during therapy with ramipril. BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.06.2009.1932. Epub 2009 Sep 15. PMID: 21918655; PMCID: PMC3029881.
Copy Download .nbib Format: NLM
Consumer interpretation of ramipril and clopidogrel medication risk information - implications for risk communication strategies.

Patient preference and adherence

Tong V, Raynor DK, Blalock SJ, Aslani P.
PMID: 26185427
Patient Prefer Adherence. 2015 Jul 09;9:983-8. doi: 10.2147/PPA.S86414. eCollection 2015.

PURPOSE: Side effects and side-effect risk information can be provided using written medicine information. However, challenges exist in effectively communicating this information to consumers. This study aimed to explore broad consumer profiles relevant to ramipril and clopidogrel side-effect risk...

Cite
Tong V, Raynor DK, Blalock SJ, et al. Consumer interpretation of ramipril and clopidogrel medication risk information - implications for risk communication strategies. Patient Prefer Adherence. 2015;9:983-8doi: 10.2147/PPA.S86414.
Tong, V., Raynor, D. K., Blalock, S. J., & Aslani, P. (2015). Consumer interpretation of ramipril and clopidogrel medication risk information - implications for risk communication strategies. Patient preference and adherence, 9983-8. https://doi.org/10.2147/PPA.S86414
Tong, Vivien, et al. "Consumer interpretation of ramipril and clopidogrel medication risk information - implications for risk communication strategies." Patient preference and adherence vol. 9 (2015): 983-8. doi: https://doi.org/10.2147/PPA.S86414
Tong V, Raynor DK, Blalock SJ, Aslani P. Consumer interpretation of ramipril and clopidogrel medication risk information - implications for risk communication strategies. Patient Prefer Adherence. 2015 Jul 09;9:983-8. doi: 10.2147/PPA.S86414. eCollection 2015. PMID: 26185427; PMCID: PMC4501347.
Copy Download .nbib Format: NLM
Notice of Retraction: Ramipril Markedly Improves Walking Ability in Patients With Peripheral Arterial Disease.

Annals of internal medicine

[No authors listed]
PMID: 26544086
Ann Intern Med. 2015 Dec 01;163(11):884. doi: 10.7326/M15-2625. Epub 2015 Nov 06.

No abstract available.

Cite
Notice of Retraction: Ramipril Markedly Improves Walking Ability in Patients With Peripheral Arterial Disease. Ann Intern Med. 2015;163(11):884doi: 10.7326/M15-2625.
(2015). Notice of Retraction: Ramipril Markedly Improves Walking Ability in Patients With Peripheral Arterial Disease. Annals of internal medicine, 163(11), 884. https://doi.org/10.7326/M15-2625
"Notice of Retraction: Ramipril Markedly Improves Walking Ability in Patients With Peripheral Arterial Disease." Annals of internal medicine vol. 163,11 (2015): 884. doi: https://doi.org/10.7326/M15-2625
Notice of Retraction: Ramipril Markedly Improves Walking Ability in Patients With Peripheral Arterial Disease. Ann Intern Med. 2015 Dec 01;163(11):884. doi: 10.7326/M15-2625. Epub 2015 Nov 06. PMID: 26544086.
Copy Download .nbib Format: NLM
Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Pharmaceuticals 2009, 2, 118-124.

Pharmaceuticals (Basel, Switzerland)

Novo S, Fazio G, Raccuglia E, Mignano A, Novo G.
PMID: 27721326
Pharmaceuticals (Basel). 2011 Sep 30;4(10):1293-1294. doi: 10.3390/ph4101293.

In the published version "Paladini et al. reported that aliskiren 300 mg provided a sustained BP-lowering effect beyond the 24-h dosing interval, with a significantly smaller loss of BP-lowering effect in the 24-48 h period after dose than irbesartan...

Cite
Novo S, Fazio G, Raccuglia E, et al. Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Pharmaceuticals 2009, 2, 118-124. Pharmaceuticals (Basel). 2011;4(10):1293-1294doi: 10.3390/ph4101293.
Novo, S., Fazio, G., Raccuglia, E., Mignano, A., & Novo, G. (2011). Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Pharmaceuticals 2009, 2, 118-124. Pharmaceuticals (Basel, Switzerland), 4(10), 1293-1294. https://doi.org/10.3390/ph4101293
Novo, Salvatore, et al. "Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Pharmaceuticals 2009, 2, 118-124." Pharmaceuticals (Basel, Switzerland) vol. 4,10 (2011): 1293-1294. doi: https://doi.org/10.3390/ph4101293
Novo S, Fazio G, Raccuglia E, Mignano A, Novo G. Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Pharmaceuticals 2009, 2, 118-124. Pharmaceuticals (Basel). 2011 Sep 30;4(10):1293-1294. doi: 10.3390/ph4101293. PMID: 27721326; PMCID: PMC4060125.
Copy Download .nbib Format: NLM
A retrospective study of antihypertensives in pemphigus: a still unchartered odyssey particularly between thiols, amides and phenols.

Archives of medical science : AMS

Pietkiewicz P, Gornowicz-Porowska J, Bowszyc-Dmochowska M, Dmochowski M.
PMID: 26528346
Arch Med Sci. 2015 Oct 12;11(5):1021-7. doi: 10.5114/aoms.2015.54857.

INTRODUCTION: Autoimmune pemphigus diseases comprise several entities with serious prognoses, including the pemphigus vulgaris (PV) group and pemphigus foliaceus (PF) group. Antihypertensives are suspected to be one of the factors triggering/sustaining pemphigus. Here, the data of pemphigus patients regarding...

Cite
Pietkiewicz P, Gornowicz-Porowska J, Bowszyc-Dmochowska M, et al. A retrospective study of antihypertensives in pemphigus: a still unchartered odyssey particularly between thiols, amides and phenols. Arch Med Sci. 2015;11(5):1021-7doi: 10.5114/aoms.2015.54857.
Pietkiewicz, P., Gornowicz-Porowska, J., Bowszyc-Dmochowska, M., & Dmochowski, M. (2015). A retrospective study of antihypertensives in pemphigus: a still unchartered odyssey particularly between thiols, amides and phenols. Archives of medical science : AMS, 11(5), 1021-7. https://doi.org/10.5114/aoms.2015.54857
Pietkiewicz, Paweł, et al. "A retrospective study of antihypertensives in pemphigus: a still unchartered odyssey particularly between thiols, amides and phenols." Archives of medical science : AMS vol. 11,5 (2015): 1021-7. doi: https://doi.org/10.5114/aoms.2015.54857
Pietkiewicz P, Gornowicz-Porowska J, Bowszyc-Dmochowska M, Dmochowski M. A retrospective study of antihypertensives in pemphigus: a still unchartered odyssey particularly between thiols, amides and phenols. Arch Med Sci. 2015 Oct 12;11(5):1021-7. doi: 10.5114/aoms.2015.54857. PMID: 26528346; PMCID: PMC4624747.
Copy Download .nbib Format: NLM
Spectral analysis of 24 h blood pressure monitoring in the assessment of trough: peak ratio. A randomized, placebo-controlled, cross-over comparison of ramipril and enalapril.

Blood pressure monitoring

Modesti PA, Toccafondi S, Carnemolla A, Rocchi F, Costoli A, Torri M, Tortoli P.
PMID: 10234131
Blood Press Monit. 1997 Dec;2(6):283-287.

BACKGROUND: The ratio between the magnitude of blood pressure reduction during the steady-state dosage interval (trough) and the maximum blood pressure reduction (peak) is an integrated in-vivo index both of the pharmacokinetic properties and of pharmacodynamic activity of an...

Cite
Modesti PA, Toccafondi S, Carnemolla A, et al. Spectral analysis of 24 h blood pressure monitoring in the assessment of trough: peak ratio. A randomized, placebo-controlled, cross-over comparison of ramipril and enalapril. Blood Press Monit. 1997;2(6):283-287
Modesti, P. A., Toccafondi, S., Carnemolla, A., Rocchi, F., Costoli, A., Torri, M., & Tortoli, P. (1997). Spectral analysis of 24 h blood pressure monitoring in the assessment of trough: peak ratio. A randomized, placebo-controlled, cross-over comparison of ramipril and enalapril. Blood pressure monitoring, 2(6), 283-287.
Modesti, et al. "Spectral analysis of 24 h blood pressure monitoring in the assessment of trough: peak ratio. A randomized, placebo-controlled, cross-over comparison of ramipril and enalapril." Blood pressure monitoring vol. 2,6 (1997): 283-287.
Modesti PA, Toccafondi S, Carnemolla A, Rocchi F, Costoli A, Torri M, Tortoli P. Spectral analysis of 24 h blood pressure monitoring in the assessment of trough: peak ratio. A randomized, placebo-controlled, cross-over comparison of ramipril and enalapril. Blood Press Monit. 1997 Dec;2(6):283-287. PMID: 10234131.
Copy Download .nbib Format: NLM
Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats.

Hypertension (Dallas, Tex. : 1979)

Rhaleb NE, Yang XP, Nanba M, Shesely EG, Carretero OA.
PMID: 11208766
Hypertension. 2001 Jan;37(1):121-128. doi: 10.1161/01.hyp.37.1.121.

-The kallikrein-kininogen-kinin system is an important vasodilator and vasodepressor component of the cardiovascular system. Acting mainly through B(2) receptors, kinins may counterbalance the pressor effect of angiotensin II, salt, and mineralocorticoids plus salt. Using rats lacking the bradykinin precursors...

Cite
Rhaleb NE, Yang XP, Nanba M, et al. Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats. Hypertension. 2001;37(1):121-128doi: 10.1161/01.hyp.37.1.121.
Rhaleb, N. E., Yang, X. P., Nanba, M., Shesely, E. G., & Carretero, O. A. (2001). Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats. Hypertension (Dallas, Tex. : 1979), 37(1), 121-128. https://doi.org/10.1161/01.hyp.37.1.121
Rhaleb, Nour-Eddine, et al. "Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats." Hypertension (Dallas, Tex. : 1979) vol. 37,1 (2001): 121-128. doi: https://doi.org/10.1161/01.hyp.37.1.121
Rhaleb NE, Yang XP, Nanba M, Shesely EG, Carretero OA. Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats. Hypertension. 2001 Jan;37(1):121-128. doi: 10.1161/01.hyp.37.1.121. PMID: 11208766.
Copy Download .nbib Format: NLM
Efficacy and Safety of Ramipril in Hypertensive Single-Kidney Patients.

American journal of therapeutics

Camaiti A, La Cava G, Del Rosso A, Arcangeli E, Federighi G.
PMID: 11850671
Am J Ther. 1995 May;2(5):328-332.

The effects of medium-term antihypertensive treatment with the ACE inhibitor ramipril were studied on 10 hypertensive single-kidney patients in a double-blind study versus placebo. Patients with renovascular hypertension were excluded. Compared to placebo, ramipril induces a significant reduction of...

Cite
Camaiti A, La Cava G, Del Rosso A, et al. Efficacy and Safety of Ramipril in Hypertensive Single-Kidney Patients. Am J Ther. 1995;2(5):328-332
Camaiti, A., La Cava, G., Del Rosso, A., Arcangeli, E., & Federighi, G. (1995). Efficacy and Safety of Ramipril in Hypertensive Single-Kidney Patients. American journal of therapeutics, 2(5), 328-332.
Camaiti, Alberto, et al. "Efficacy and Safety of Ramipril in Hypertensive Single-Kidney Patients." American journal of therapeutics vol. 2,5 (1995): 328-332.
Camaiti A, La Cava G, Del Rosso A, Arcangeli E, Federighi G. Efficacy and Safety of Ramipril in Hypertensive Single-Kidney Patients. Am J Ther. 1995 May;2(5):328-332. PMID: 11850671.
Copy Download .nbib Format: NLM
Is Ramipril the pril for diabetes and kidney disease?.

Drugs of today (Barcelona, Spain : 1998)

Doggrell SA.
PMID: 12768220
Drugs Today (Barc). 2001 May;37(5):321-331. doi: 10.1358/dot.2001.37.5.627954.

Ramipril is safe and effective in the treatment of hypertension and heart failure, but this is not reviewed here. Ramipril is a lipophilic angiotensin-converting enzyme inhibitor suitable for once-daily administration. In addition to decreasing angiotensin II and increasing bradykinin...

Cite
Doggrell SA. Is Ramipril the pril for diabetes and kidney disease?. Drugs Today (Barc). 2001;37(5):321-331doi: 10.1358/dot.2001.37.5.627954.
Doggrell, S. A. (2001). Is Ramipril the pril for diabetes and kidney disease?. Drugs of today (Barcelona, Spain : 1998), 37(5), 321-331. https://doi.org/10.1358/dot.2001.37.5.627954
Doggrell, Sheila A.. "Is Ramipril the pril for diabetes and kidney disease?." Drugs of today (Barcelona, Spain : 1998) vol. 37,5 (2001): 321-331. doi: https://doi.org/10.1358/dot.2001.37.5.627954
Doggrell SA. Is Ramipril the pril for diabetes and kidney disease?. Drugs Today (Barc). 2001 May;37(5):321-331. doi: 10.1358/dot.2001.37.5.627954. PMID: 12768220.
Copy Download .nbib Format: NLM
A novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design [ISRCTN55725285].

Current controlled trials in cardiovascular medicine

Pater C, Bhatnagar D, Berrou JP, Luszick J, Beckmann K.
PMID: 15461784
Curr Control Trials Cardiovasc Med. 2004 Oct 01;5(1):9. doi: 10.1186/1468-6708-5-9.

Hypertension and diabetes mellitus are closely interrelated and coexist in as many as two-thirds of patients with type 2 diabetes. The consequent risk of such an association is an accelerated development of atherosclerotic cardiovascular disease and nephropathy complications.In choosing...

Cite
Pater C, Bhatnagar D, Berrou JP, et al. A novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design [ISRCTN55725285]. Curr Control Trials Cardiovasc Med. 2004;5(1):9doi: 10.1186/1468-6708-5-9.
Pater, C., Bhatnagar, D., Berrou, J. P., Luszick, J., & Beckmann, K. (2004). A novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design [ISRCTN55725285]. Current controlled trials in cardiovascular medicine, 5(1), 9. https://doi.org/10.1186/1468-6708-5-9
Pater, Cornel, et al. "A novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design [ISRCTN55725285]." Current controlled trials in cardiovascular medicine vol. 5,1 (2004): 9. doi: https://doi.org/10.1186/1468-6708-5-9
Pater C, Bhatnagar D, Berrou JP, Luszick J, Beckmann K. A novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design [ISRCTN55725285]. Curr Control Trials Cardiovasc Med. 2004 Oct 01;5(1):9. doi: 10.1186/1468-6708-5-9. PMID: 15461784; PMCID: PMC524514.
Copy Download .nbib Format: NLM
Commentary. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial.

Perspectives in vascular surgery and endovascular therapy

Oldenburg WA.
PMID: 17460852
Perspect Vasc Surg Endovasc Ther. 2007 Mar;19(1):89-91.

No abstract available.

Cite
Oldenburg WA. Commentary. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Perspect Vasc Surg Endovasc Ther. 2007;19(1):89-91
Oldenburg, W. A. (2007). Commentary. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Perspectives in vascular surgery and endovascular therapy, 19(1), 89-91.
Oldenburg, W Andrew. "Commentary. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial." Perspectives in vascular surgery and endovascular therapy vol. 19,1 (2007): 89-91.
Oldenburg WA. Commentary. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Perspect Vasc Surg Endovasc Ther. 2007 Mar;19(1):89-91. PMID: 17460852.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 213 entries